SH0:F:F-Shionogi & Co. Ltd (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 43

Change

+0.60 (+1.42)%

Market Cap

USD 12.76B

Volume

45.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRK:F Merck & Company Inc

-0.50 (-0.32%)

USD 66.78B
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 65.62B
ZOE:F Zoetis Inc

+2.00 (+1.31%)

USD 64.18B
TKD:F Takeda Pharmaceutical Company ..

-0.21 (-0.87%)

USD 39.41B
TKDA:F Takeda Pharmaceutical Company ..

-0.30 (-2.46%)

USD 38.72B
H6D0:F Haleon PLC

-0.04 (-1.12%)

USD 35.13B
H6D:F Haleon PLC

-0.10 (-1.36%)

USD 35.12B
TEV:F Teva Pharmaceutical Industries..

-0.10 (-0.67%)

USD 14.69B
NB3:F Neurocrine Biosciences Inc

-0.80 (-0.61%)

USD 12.70B
RDDA:F Dr. Reddy's Laboratories Limit..

-1.00 (-1.52%)

USD 11.53B

ETFs Containing SH0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.47% 49% F 50% F
Dividend Return 175.23% 71% C- 89% A-
Total Return 175.70% 95% A 96% N/A
Trailing 12 Months  
Capital Gain 5.91% 70% C- 59% D-
Dividend Return 369.46% 87% B+ 91% A-
Total Return 375.37% 97% N/A 97% N/A
Trailing 5 Years  
Capital Gain -16.28% 59% D- 33% F
Dividend Return 712.62% 86% B+ 89% A-
Total Return 696.34% 94% A 93% A
Average Annual (5 Year Horizon)  
Capital Gain -2.59% 57% F 39% F
Dividend Return 121.02% 98% N/A 96% N/A
Total Return 123.61% 88% B+ 86% B+
Risk Return Profile  
Volatility (Standard Deviation) 104.05% 6% D- 8% B-
Risk Adjusted Return 116.31% 100% F 99% N/A
Market Capitalization 12.76B 96% N/A 88% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector